Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Fractyl Health, Inc., retaining the price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Whitney Ijem has given his Buy rating due to a combination of factors surrounding Fractyl Health, Inc.’s ongoing developments and potential market opportunities. The company’s Revita procedure, currently in a Phase 3 trial, shows promise in weight maintenance, with experts indicating that controlled data will be crucial to fully understand its clinical profile and durability. Despite some skepticism regarding the mechanism, there is consensus among key opinion leaders that the procedure has an effect, and even conservative market share estimates suggest significant potential.
Furthermore, the company’s peak sales projections for Revita and the potential for their GLP-1 gene therapy contribute to the positive outlook. The market’s response to the early data, coupled with the anticipation of more comprehensive results in the future, underpins the Buy rating. Whitney Ijem’s analysis suggests that even with a cautious approach, the upside potential for Fractyl Health, Inc. remains substantial, warranting the current recommendation.
GUTS’s price has also changed slightly for the past six months – from $1.800 to $1.790, which is a -0.56% drop .